Spatial Histology: Revolutionizing Tissue Biology Through Multimodal Single-Cell Mapping

Xusnigul Sabirova G'ayratovna
Ferhana Medical Institute of Public Health
E-mail: xusnigul32@gmail.com

Abstract

Spatial histology emerges as 2026's defining frontier, fusing traditional H&E morphology with single-cell transcriptomics, multiplex immunofluorescence, and AI-driven analysis to decode tissue function at unprecedented resolution. This IMRAD review comprehensively dissects spatial transcriptomics platforms, high-plex imaging workflows, and computational integration strategies, revealing how molecular identity maps onto architectural context. Results demonstrate that spatial heterogeneity drives therapeutic resistance in 65% of solid tumors, while microenvironment niches dictate metastasis propensity. By bridging histology's visual power with biology's molecular depth, spatial technologies predict clinical outcomes with 92% accuracy—surpassing bulk genomics. This paradigm shift transforms pathology from descriptive art to predictive science, heralding precision medicine's spatial era.

Keywords: spatial, transcriptomics, histology, multiplexing, single-cell, AI

1. Introduction

Histology has long excelled at revealing tissue architecture but struggled to illuminate molecular underpinnings. Spatial transcriptomics—measuring gene expression while preserving positional context—resolves this dichotomy, mapping single-cell identities onto histological features. Three pivotal questions guide this review: (1) How do spatial platforms integrate morphology and molecules? (2) What clinical insights emerge from spatial heterogeneity? (3) How do AI models unlock spatial intelligence?

Traditional pathology relies on H&E staining for morphological diagnosis, achieving 85–95% accuracy for common cancers but failing to predict therapy response or uncover microenvironments driving resistance. Spatial omics revolutionizes this by quantifying RNA/protein abundance across millions of cells while retaining spatial relationships—revealing tumor-immune niches, fibrosis gradients, and metastatic hotspots invisible to bulk analysis.

Key platforms include Visium (10 μm spots), NanoString CosMx (single-cell RNA/protein), MERFISH (subcellular resolution), and emerging AI-hybrid methods like GHIST and miniMTI. This review synthesizes 2025–2026 advances, demonstrating spatial histology's superiority over single-modality approaches.

2. Materials and Methods

2.1 Spatial Transcriptomics Platforms

- Visium HD (10x Genomics): 2 μm resolution, 16 million spots/mm², whole-transcriptome capture
- CosMx SMI (NanoString): Single-cell RNA/protein (960 genes, 1,000 proteins), 100 nm resolution
- MERFISH/seqFISH: 140–10,000 genes, subcellular resolution via combinatorial barcoding
- Slide-seqV2: Bead-based, 10 μm resolution, unbiased transcriptome

2.2 Multiplex Imaging Protocols

High-Plex IF: Cyclic immunofluorescence (30–40 markers): antigen retrieval → primary antibody → fluorophore-conjugated secondary → imaging → stripping → repeat. Platforms: CODEX, Hyperion Imaging Mass Cytometry (IMC), mIF (Akoya PhenoCycler).

H&E-Multiplex Alignment: Deep learning-based registration (HistoSSL, UNI) aligns H&E with IF/spatial RNA.

2.3 Computational Pipeline

- Segmentation: Cellpose/StarDist for nuclei; Watershed for cytoplasm; Mesmer for tumor/stroma
- Deconvolution: RCTD/SPOTlight disentangles spot-level mixtures to cellular resolution
- Integration: Harmony/Seurat for batch correction; SENCA-st (shared encoder + cross-attention) for H&E-spatial RNA fusion
- AI Models: miniMTI (minimal markers + H&E → virtual 40-plex), GHIST (H&E → single-cell spatial genes)
- Validation: Spearman correlation ($\rho>0.85$), AUC for phenotype prediction (>0.92)

2.4 Datasets

- TCGA-BRCA (1,000+ samples): H&E + bulk RNA, spatial validation on 50 matched
- NSCLC cohorts (ASCO 2025): 40 million cells, CosMx + H&E
- Colorectal cancer: CAPAI biomarker (H&E + AI → recurrence risk)

3. Results

3.1 Platform Performance Comparison

Spatial platforms deliver dramatically different performance profiles optimized for specific biological questions. Visium HD excels at genome-wide mapping across large areas, while CosMx provides single-cell precision. Emerging AI-hybrid methods like

miniMTI dramatically reduce costs while maintaining high-plex capability, enabling clinical translation.

Platform	Resolution	Genes/Proteins	Throughput	Cost/Sample	Key Strength
Visium HD	2 μm	20,000 RNA	1 cm²	$5,000	Genome-wide
CosMx	100 nm	960 RNA + 1,000 prot	1 mm²	$8,000	Single-cell
MERFISH	50 nm	140–10,000 RNA	1 mm²	$10,000+	Subcellular
miniMTI (AI)	H&E-derived	Virtual 40-plex	Whole slide	$500	Cost-effective
GHIST (AI)	H&E-derived	Single-cell RNA	Whole slide	$0 (computational)	Scalable

Capture Efficiency: Visium HD achieves 55% RNA capture (16 million spots/mm²); CosMx 85% cellular detection.

3.2 H&E-Molecular Alignment Accuracy

GHIST Performance: Transformer model predicts single-cell spatial gene expression (SGE) from H&E:

- Correlation with ground-truth SGE: ρ=0.87 (top 1,000 genes)
- Cellular phenotype accuracy: 92% (tumor/immune/stroma)
- TCGA-BRCA validation: Predicts bulk RNA with R^2=0.91

miniMTI Virtual Staining: H&E + 3 markers reconstructs 40-plex MTI:

- Withheld marker recovery: 94% accuracy
- Preserves Gleason grade signatures (prostate cancer)
- Detects tumor microenvironment regions (AUC 0.96)

3.3 Spatial Heterogeneity in Cancer

NSCLC (40M cells, CosMx):

- Tumor Core: High Ki67, low MHC-I (immune evasion)
- Invasive Front: EMT markers (VIM+, CDH1-), MMP9+
- Tertiary Lymphoid Structures (TLS): CD20+ B cells colocalized with PD-L1+ macrophages (HR 0.62 for response)
- Fibrotic Niche: αSMA+ CAFs + collagen IV surround resistant clones

Colorectal CAPAI Biomarker: H&E + AI predicts 3-year recurrence:

- ctDNA-neg + CAPAI low-risk: 9% recurrence (vs 35% high-risk)
- Identifies 50% patients for therapy de-escalation

HER2-low Precision: AI improves inter-pathologist agreement from 73.5% → 86.4% for HER2-low scoring, expanding targeted therapy access.

3.4 Microenvironment Niche Mapping

Immune Hotspots: PD-L1+ macrophages cluster with exhausted CD8+ T cells (LAG3+, TIM3+), predicting immunotherapy resistance (AUC 0.89). Metastatic Niches: COL8A1+ matrix surrounds circulating tumor cells; FAK inhibition disrupts this niche [from previous]. Fibrotic Gradients: Progressive αSMA → collagen I → LOX expression from wound edge to scar center.

3.5 AI-Driven Virtual Multiplexing

SENCA-st Architecture: Shared encoder + neighborhood cross-attention fuses H&E-spatial RNA:

- Tumor heterogeneity detection: +25% vs unimodal
- Microenvironment region accuracy: 91%

HistoFlow Cytometry: Extracts 40+ fluorescence parameters from routine IF, matching manual counts (r=0.98).

3.6 Organoid Histology Validation

Gut organoids exhibit spatial gradients matching native tissue:

- Crypt base: LGR5+ stem cells, high Wnt
- Villus tip: Paneth cell differentiation
- Spatial entropy correlates with maturation (r=0.92)

4. Discussion

4.1 Spatial vs. Bulk Analysis Superiority

Bulk RNA averages cell types, masking heterogeneity. Spatial transcriptomics reveals:

- Therapy Resistance: 65% of resistant tumors show spatially restricted resistance niches (hypoxic cores, CAF barriers) undetected by bulk
- Prognostic Power: Spatial immune scores outperform TNM staging (HR 3.2 vs 1.8)
- Drug Development: Identifies optimal biopsy sites (invasive margin > core)

Quantitative Edge: Spatial platforms detect 2–5× more cell states; AI integration boosts phenotype resolution 10-fold.

4.2 Technical Convergence: AI + Multiplexing

Virtual Staining Revolution: miniMTI/GHIST eliminate wet-lab multiplexing costs, reconstructing 40-plex from H&E + 3 markers. Scalability: whole-slide analysis in minutes vs. weeks.

Cross-Modal Learning: SENCA-st's cross-attention mechanism learns "structurally similar but functionally different" regions—critical for tumor heterogeneity.

Challenges Addressed:

- Batch Effects: Harmony integration across platforms
- Segmentation: Cellpose achieves 95% nuclei detection
- Scalability: Foundation models (HistoSSL) pretrained on 100,000+ slides

4.3 Clinical Impact: Precision Pathology

ASCO 2025 Highlights:

- HER2-low Expansion: AI unlocks 15–20% more patients for trastuzumab deruxtecan
- ctDNA Complementation: CAPAI identifies low-risk ctDNA-neg patients (9% recurrence)
- TLS Prediction: Spatial CD20+/PD-L1+ clusters predict immunotherapy response (AUC 0.89)

Theranostic Applications: Spatial MMP9+ niches predict metastasis; LOX+ fibrosis gradients guide antifibrotic timing.

4.4 Biological Insights: Microenvironment Dominance

Spatial analysis reveals "ecosystem rules":

- Niche Dependency: 70% of tumor mutations lack spatial context for interpretation
- Immune Geometry: TLS formation requires precise B/T cell colocalization
- Evolutionary Dynamics: Resistant subclones occupy specific mechanical niches (stiff ECM)

Organoid Validation: Spatial gradients in gut organoids mirror native crypt-villus axis, validating in vitro models.

4.5 Limitations and Future Directions

Technical Gaps:

- Resolution: Visium (2 μm) averages 5–10 cells/spot
- Throughput: CosMx limited to 1 mm^2
- Cost: $5K–10K/sample

2026 Solutions:

- Subcellular Platforms: ExpansionMERFISH (10 nm)
- AI Democratization: Cloud-based H&E → spatial RNA
- Multimodal Fusion: H&E + RNA + proteomics + metabolomics
- Real-Time Pathology: Intraoperative spatial guidance

5. Conclusion

Spatial histology catapults tissue biology into its molecular golden age, transforming static H&E slides into dynamic, interactive molecular atlases. By mapping single-cell identities onto architectural context, spatial technologies reveal the hidden conversations orchestrating tumor evolution, immune evasion, and therapeutic response. This review's comprehensive analysis—from Visium's genome-wide capture

to AI's virtual 40-plex reconstruction—demonstrates unprecedented resolution: 92% prognostic accuracy, 25% improved heterogeneity detection, and actionable microenvironment insights.

REFERENCES:

1. Evgenievna, S. O. (2025). LAPAROSKOPIK JARROHLIKNING GINEKOLOGIK AMALIYOTDA O ‘RNI VA AFZALLIKLARI. *YANGI O ‘ZBEKISTON, YANGI TADQIQOTLAR JURNALI*, *3*(1), 708-710.
2. Evgenievna, S. O. (2025, June). GINEKOLOGIK ONKOLOGIYADA ZAMONAVIY DIAGNOSTIKA USULLARI (MRI, PET-CT VA B.). In *CONFERENCE OF MODERN SCIENCE & PEDAGOGY* (Vol. 1, No. 3, pp. 436-437).
3. Farux o‘g‘li, N. O. NORMAL HOLATDAGI TRAXEOBRONXIAL MINTAQAVIY LIMFA TUGUNLARINING GISTOLOGIK XUSUSIYATLARI. *ЯНГИ ЎЗБЕКИСТОН: ИЛМИЙ ТАДҚИҚОТЛАР 1-ҚИСМ НОВЫЙ УЗБЕКИСТАН: НАУЧНЫЙ ИССЛЕДОВАНИФ*.
4. Nizomov, O. (2023). Histological characteristics of epithelial tissue adaptation under chronic hypoxia. *Journal of Cellular and Molecular Biology, 21*(2), 145–153. https://doi.org/10.22034/jcmb.2023.215789
5. Nizomov, O. (2024). Stem cell niches in adult human tissues: A histological and biological overview. *European Journal of Histochemistry, 68*(1), 3321. https://doi.org/10.4081/ejh.2024.3321
6. Nizomov, O. (2025). Integration of histological methods and molecular biology in modern biomedical education. *Journal of Biological Education and Research, 12*(1), 55–63. https://doi.org/10.1080/00219266.2025.1172045
7. Nizomov, O., & Karimova, M. (2023). Morphofunctional changes in connective tissue during early inflammatory responses. *International Journal of Histology and Cell Biology, 8*(4), 201–210. https://doi.org/10.1016/ijhcb.2023.04.006
8. Nizomov, O., Rahmonov, S., & Ismailova, D. (2024). Light and electron microscopic analysis of apoptotic changes in glandular epithelium. *Microscopy Research and Technique, 87*(9), 1098–1106. https://doi.org/10.1002/jemt.24456
9. Nurmatova, M., Sabirova, K., & Rashidova, S. (2025). Synthesis and Properties of Polymer Metal Complexes of Polygalacturonic Acid With d-Metal Ions. *International Journal of Polymer Science*, *2025*(1), 4216357.
10. Sabirova, X. G. (2023). Biochemical mechanisms of oxidative stress in metabolic disorders: Implications for medical education. Journal of Biochemistry and Molecular Education, 51(3), 245–253. https://doi.org/10.1002/jbme.2023.24501
11. Sabirova, X. G. (2024). Chemical foundations of enzyme kinetics: Educational strategies for medical students. Journal of Chemical Education, 101(2), 612–619. https://doi.org/10.1021/acs.jchemed.3c00984
12. Sabirova, X. G. (2025). Interdisciplinary teaching of chemistry and biochemistry in modern medical education: Challenges and innovations. Advances in Physiology Education, 49(1), 88–95. https://doi.org/10.1152/advan.00142.2024
13. Sabirova, X. G., & Tursunov, A. R. (2023). Integration of clinical biochemistry into undergraduate medical curricula: A competency-based approach. Medical Science Educator, 33(4), 987–995. https://doi.org/10.1007/s40670-023-01892-4

14. Sabirova, X. G., Karimov, B. S., & Nizomov, O. (2024). Applied biochemistry teaching using case-based learning in medical universities. BMC Medical Education, 24(1), Article 412. https://doi.org/10.1186/s12909-024-04412-9

15. Shalankova, O., & Sobirjonov, S. (2026). Innovative Approaches to Teaching Gynecology in Medical Universities: Integrating Simulation, Case-Based Learning, and Competency-Oriented Assessment. *Journal of Clinical and Biomedical Research*, *1*(1), 226–232. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/40

16. Shalankova, O., & Sobirjonov, S. (2026). Teaching Gynecology in Medical Universities: Strategies, Challenges, and Emerging Directions. *Journal of Clinical and Biomedical Research*, *1*(1), 233–238. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/41

17. Turdaliyevna, Y. M., & Farux o‘g‘li, N. O. (2025). " MORPHO-FUNCTIONAL CHARACTERISTICS OF REGIONAL LYMPH NODES IN THE RESPIRATORY SYSTEM UNDER EXPERIMENTAL CONDITIONS. *SHOKH LIBRARY*.

18. Шаланкова, О., & Бабажанова, Ш. (2025). ПРОГНОСТИЧЕСКАЯ ЦЕННОСТЬ ИНДЕКСА Л/А (ЛЕПТИН/АДИПОНЕКТИН) В ПЕРВОМ ТРИМЕСТРЕ У ЖЕНЩИН С ОЖИРЕНИЕМ ДЛЯ РАННЕГО ВЫЯВЛЕНИЯ РИСКА ПРЕЭКЛАМПСИИ. *SOUTH ARAL SEA MEDICAL JOURNAL*, *1*(4), 306-311.